Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis.
Berend J van WelzenSteven F L Van LelyveldGerjanne Ter BeestJet H GisolfSuzanne E GeerlingsJan M PrinsGitte Van TwillertCees Van NieuwkoopMarc Van der ValkDavid BurgerAnnemarie M J WensingPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
This is the first in-depth multiple case analysis of VF on LA CAB/RPV therapy in a real-world setting. Our observations stress the need to be aware for (evolving) risk factors and the yield of a comprehensive clinical, virological and pharmacokinetic approach in case of failure.